The drugmaker's financial results are also impressive, spearheaded by tirzepatide, a therapy for diabetes and obesity that is ...

Eli Lilly's valuation could look much more modest in the future, as its earnings should continue to grow at a high rate.

Eli Lilly’s senior VP of information and R&D IT, Ramesh Durvasula, said Lilly will use AI and tech to transform the company.

Ministers want to examine the impact of the weight loss drug tirzepatide on people’s health outcomes and employment status. Elisabeth Mahase looks at how the study will work A new partnership between ...

Britain will study whether the use of Eli Lilly’s weight loss drug can get people back into work and help tackle the high ...

Hims stock has rallied almost 22% this week on enthusiasm after the FDA said it will allow compounded versions of Lilly's ...

It is primary aim is to analyse how tirzepatide, sold by Eli Lilly under the brand name Mounjaro, reduces obesity and other ...

The U.S. Food and Drug Administration (FDA) is rethinking its decision to remove popular weight-loss and diabetes drugs from ...

This week’s news from the life sciences includes Eli Lilly's investment in a Cambridge-Singapore biotech, Stealth ...

The tax rate is 40 per cent, but it’s only charged on the part of the estate that’s above the threshold. In 2023/24, only 5 per cent of deaths generated an inheritance tax bill, raising around £7 ...

The UK’s life sciences sector will receive £279 million from drugs giant Eli Lilly, to invest in developing new medicines and ways to deliver treatment. “The long-term benefits of these drugs could be ...